Quince Therapeutics Reports Officer & Director Changes, Compensation
Ticker: QNCX · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $38,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Quince Therapeutics is shaking up its leadership and compensation structure, signaling potential strategic shifts.**
AI Summary
Quince Therapeutics, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 13, 2024. The filing indicates changes in the company's leadership, specifically addressing the departure of directors or certain officers, the election of new directors, and the appointment of certain officers. Additionally, the report covers compensatory arrangements for these officers, signaling potential shifts in executive structure and compensation at Quince Therapeutics.
Why It Matters
Changes in leadership and executive compensation can significantly impact a company's strategic direction and operational stability, influencing investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation can introduce uncertainty or signal strategic shifts, which carry inherent risks depending on the individuals involved and the reasons for the changes.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — registrant
- February 13, 2024 (date) — date of earliest event reported
- February 15, 2024 (date) — filing date
FAQ
What is the primary purpose of this 8-K filing by Quince Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 13, 2024.
When was this 8-K filing filed with the SEC?
This 8-K filing was filed with the SEC on February 15, 2024.
What is the state of incorporation for Quince Therapeutics, Inc.?
Quince Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Quince Therapeutics, Inc.?
The Commission File Number for Quince Therapeutics, Inc. is 001-38890.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-02-15 16:00:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX Nasdaq Global Select
- $38,000 — icy, Mr. Patni is entitled to receive a $38,000 annual retainer for service as a Board
Filing Documents
- d791068d8k.htm (8-K) — 27KB
- 0001193125-24-037521.txt ( ) — 181KB
- qncx-20240213.xsd (EX-101.SCH) — 4KB
- qncx-20240213_def.xml (EX-101.DEF) — 13KB
- qncx-20240213_lab.xml (EX-101.LAB) — 22KB
- qncx-20240213_pre.xml (EX-101.PRE) — 14KB
- d791068d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Quince Therapeutics, Inc. By: /s/ Dirk Thye Date: February 15, 2024 Name: Dirk Thye Title: Chief Executive Officer